HEBP2 Inhibitors
Chemical inhibitors of HEBP2 operate through various biochemical pathways to diminish the protein's functional activity. Allopurinol, by inhibiting xanthine oxidase, reduces the production of reactive oxygen species, which may be critical for HEBP2's oxidative stress-related functions. Similarly, Auranofin targets the cellular redox state by inhibiting thioredoxin reductase, which could attenuate HEBP2 activity that relies on redox-sensitive mechanisms. Chelerythrine's role as a protein kinase C (PKC) inhibitor suggests that it might reduce HEBP2 activity through decreased PKC-mediated phosphorylation, while Imatinib and Sodium orthovanadate target the protein's activity by modulating tyrosine phosphorylation, with Imatinib inhibiting certain tyrosine kinases and Sodium orthovanadate inhibiting tyrosine phosphatases. This phosphorylation modulation can alter HEBP2's function, as its activity may depend on the precise state of phosphorylation.
The PI3K inhibitors LY294002 and Wortmannin can impede the localization or activity of HEBP2 by preventing signaling events necessary for its function. Rapamycin, as an mTOR pathway inhibitor, could similarly disrupt pathways essential for HEBP2's activity. The MAPK/ERK pathway is another target, with U0126 and PD98059 acting as inhibitors of MAPK/ERK and MEK respectively, potentially leading to a decrease in HEBP2 activity. SB203580 and SP600125 also target the MAPK pathway but at different nodes; SB203580 specifically inhibits p38 MAP kinase, and SP600125 targets c-Jun N-terminal kinase (JNK). By inhibiting these kinases, both chemicals can decrease the downstream effects that facilitate HEBP2's role in stress response pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol is a xanthine oxidase inhibitor that can lead to reduced production of reactive oxygen species (ROS). Since HEBP2 has been implicated in cellular responses to oxidative stress, the reduction in ROS can diminish the functional activity of HEBP2 as it may have less oxidative by-products to bind to and act upon. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is a potent inhibitor of protein kinase C (PKC). HEBP2's function could be regulated by PKC-mediated phosphorylation; thus, inhibition of PKC can result in decreased functional activity of HEBP2 due to reduced phosphorylation states. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. If HEBP2 function is dependent on PI3K signaling for membrane localization or activity, inhibition of PI3K can reduce the functional activity of HEBP2 by preventing its proper localization or action within the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase (MAPK/ERK). As HEBP2 may be involved in the MAPK signaling pathway, inhibition of MAPK can decrease the downstream effects where HEBP2 is functionally active, thus diminishing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. If HEBP2 operates downstream of p38 MAPK in stress response pathways, inhibition of p38 MAPK can reduce the functional involvement of HEBP2 in these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor which can inhibit the MAPK/ERK pathway upstream. HEBP2, if it is reliant on the MAPK/ERK pathway for its activity, would have reduced functional activity due to upstream inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. If PI3K activity is necessary for the full functional activity of HEBP2, its inhibition by Wortmannin would result in a decrease in HEBP2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since HEBP2 might be involved in pathways regulated by mTOR, its inhibition by Rapamycin could lead to a reduction in HEBP2 activity by impeding a pathway necessary for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Given that HEBP2 may act downstream of JNK in response to cellular stress, inhibition of JNK can reduce the functional activity of HEBP2. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that can inhibit the ABL family of tyrosine kinases. If HEBP2 is functionally regulated by tyrosine phosphorylation through ABL kinases, Imatinib could reduce its activity by inhibiting this post-translational modification. | ||||||